Caribou Biosciences, Inc. (CRBU)

Several events have impacted Caribou Biosciences' stock price in the past six months. In November 2025, positive interim data from Phase 1 trials of CB-010 and CB-011 led to stock volatility but hinted at fresh optimism. In April 2025, a strategic pipeline prioritization focusing on CB-010 and CB-011 included workforce and cost reduction initiatives. In January 2026, Bank of America Securities lowered its price target to $6 from $8 but maintained a "Buy" rating. In February 2026, Clear Street initiated coverage with a "buy" recommendation, citing its CAR-T pipeline. In February 2026, Caribou Biosciences announced late-breaking presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®. Over the past year, CRBU's stock has experienced a 9.630% change, with a 52-week range between $0.66 and $3.54.

As a clinical-stage biopharmaceutical company, Caribou Biosciences' revenue is primarily tied to research and development milestones, collaborations, and potential future product approvals. There is no readily available information or indication of demand seasonality for Caribou Biosciences' products and services in the traditional sense. Stock market performance may show seasonality, but this does not directly translate to seasonality in the demand for its therapeutic products, which are still in clinical development.

Caribou Biosciences, Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing therapies for devastating diseases. They operate in the biotechnology and medical research industry, utilizing their CRISPR-Cas gene-editing platform to create next-generation, genome-edited cell therapies. Their major products are a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies designed for hematologic malignancies, solid tumors, autoimmune diseases, and monogenic disorders. Key product candidates include CB-010 for B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus; CB-011 for relapsed or refractory multiple myeloma; and CB-012 for relapsed or refractory acute myeloid leukemia.

Caribou Biosciences, Inc. is headquartered in Berkeley, California, and was co-founded in 2011 by Nobel laureate Jennifer Doudna. The company's operations are primarily in the United States, which generates the maximum revenue, and it also has a presence in the "Rest of the World." Caribou continues to conduct trials across multiple regions, aiming to bring its therapies to patients worldwide.

Caribou Biosciences' brand reputation in the past year appears to be mixed but with a leaning towards positive sentiment from analysts regarding its clinical pipeline. The company has received a consensus rating of "Hold" from some analysts, while others have given a "Strong Buy" consensus rating based on analysis from 3 analysts. Some analysts have a bullish consensus with a median price target implying significant upside. Positive clinical trial data for CAR-T therapies generated attention and optimism. Strategic pipeline prioritization and workforce reduction reflected operational challenges. Analyst upgrades and initiations from firms like Clear Street and Bank of America Securities indicate increasing optimism.

Caribou Biosciences, Inc. has a diverse ownership structure, with institutional investors holding approximately 39.75% of the stock, insiders owning about 8.81%, and retail investors holding around 51.44%. Major institutional owners include Pfizer Inc, Vanguard Group Inc, Millennium Management LLC, Kynam Capital Management, LP, BlackRock, Inc., Standard Life Aberdeen plc, PFM Health Sciences, LP, and Two Sigma Advisers, LP. The largest individual shareholder is Rachel E. Haurwitz, the President and CEO, who owns 3,664,845 shares, representing 3.92% of the company.